CY1106974T1 - Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας - Google Patents

Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας

Info

Publication number
CY1106974T1
CY1106974T1 CY20071101414T CY071101414T CY1106974T1 CY 1106974 T1 CY1106974 T1 CY 1106974T1 CY 20071101414 T CY20071101414 T CY 20071101414T CY 071101414 T CY071101414 T CY 071101414T CY 1106974 T1 CY1106974 T1 CY 1106974T1
Authority
CY
Cyprus
Prior art keywords
weight loss
treatment
multiple chinese
phentermine
present
Prior art date
Application number
CY20071101414T
Other languages
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus, Inc. filed Critical Vivus, Inc.
Publication of CY1106974T1 publication Critical patent/CY1106974T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Η παρούσα εφεύρεση χαρακτηρίζει μια νέα θεραπεία για επιτέλεση απώλειας βάρους η οποία περιλαμβάνει τη θεραπεία ενός υποκειμένου με ένα συμπαθητικομιμητικό παράγοντα (π.χ., φαινοτερμίνη ή ένα όμοιο με φαινοτερμίνη φάρμακο) σε συνδυασμό με ένα αντισπασμωδικό σουλφαμικό παράγωγο (π.χ., τοπιραμικό) έτσι ώστε το υποκείμενο να βιώσει απώλεια βάρους. Οι μέθοδοι συνδυασμού της παρούσας εφεύρεσης είναι επίσης αποτελεσματικές ενάντια στα συμπτώματα που συνδέονται με το σύνδρομο Χ. Η εφεύρεση χαρακτηρίζει επίσης φαρμακευτικές συνθέσεις και συλλογές για χρήση στην πρακτική άσκηση αυτών των νέων θεραπειών.
CY20071101414T 1999-06-14 2007-11-05 Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας CY1106974T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09
EP00939884A EP1187603B1 (en) 1999-06-14 2000-06-14 Combination therapy for effecting weight loss and treating obesity

Publications (1)

Publication Number Publication Date
CY1106974T1 true CY1106974T1 (el) 2012-09-26

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101414T CY1106974T1 (el) 1999-06-14 2007-11-05 Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας

Country Status (10)

Country Link
EP (5) EP1187603B1 (el)
AT (1) ATE369126T1 (el)
AU (1) AU770068B2 (el)
CA (2) CA2377330C (el)
CY (1) CY1106974T1 (el)
DE (1) DE60035870T2 (el)
DK (1) DK1187603T3 (el)
ES (4) ES2291215T3 (el)
PT (1) PT1187603E (el)
WO (1) WO2000076493A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
JP4920163B2 (ja) 2000-07-07 2012-04-18 オーソーマクニール ファーマシューティカル， インコーポレイテッド Ｉｉ型糖尿病およびｘ症候群の進行を防止するのに有用な鎮痙剤誘導体
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP1333887B1 (en) * 2000-10-30 2006-08-02 Ortho-McNeil Pharmaceutical, Inc. Combination therapy comprising anti-diabetic and anticonvulsant agents
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
CN1320886C (zh) 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
PL375813A1 (en) * 2002-12-13 2005-12-12 Cilag Ag Stable topiramate formulations
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
BRPI0506829A (pt) * 2004-01-13 2007-05-29 Univ Duke composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007014613A (es) 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
RU2452471C2 (ru) * 2006-11-09 2012-06-10 Ориксиджен Терапьютикс, Инк. [Сша/Сша] Слоистые фармацевтические составы
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US9597220B2 (en) 2008-11-19 2017-03-21 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
WO2011085331A1 (en) 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
KR20210012056A (ko) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
PL2961350T3 (pl) 2013-02-27 2018-07-31 Spirox, Inc. Implanty i systemy nosowe
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
WO2015082645A1 (en) 2013-12-05 2015-06-11 Givaudan Sa Organic compounds
WO2016033196A1 (en) 2014-08-26 2016-03-03 Spirox, Inc. Nasal implants and systems and method of use
CN113349985A (zh) 2015-09-25 2021-09-07 斯贝洛克斯公司 鼻植入物和系统及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
EP2305228B1 (en) 2015-05-06
EP2305228A1 (en) 2011-04-06
ES2542892T3 (es) 2015-08-12
ATE369126T1 (de) 2007-08-15
CA2377330A1 (en) 2000-12-21
ES2542868T3 (es) 2015-08-12
EP2308481B1 (en) 2015-05-06
AU770068B2 (en) 2004-02-12
EP1187603A1 (en) 2002-03-20
EP2305226A1 (en) 2011-04-06
ES2542891T3 (es) 2015-08-12
EP2305227B1 (en) 2015-05-06
CA2377330C (en) 2009-11-24
EP1187603B1 (en) 2007-08-08
WO2000076493A1 (en) 2000-12-21
ES2291215T3 (es) 2008-03-01
PT1187603E (pt) 2007-11-16
DK1187603T3 (da) 2007-12-17
DE60035870T2 (de) 2008-05-08
EP2308481A1 (en) 2011-04-13
EP1187603A4 (en) 2004-02-11
DE60035870D1 (de) 2007-09-20
EP2305227A1 (en) 2011-04-06
CA2686633A1 (en) 2000-12-21
EP2305226B1 (en) 2015-05-06
AU5489600A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
CY1106974T1 (el) Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
PT1333887E (pt) Metodo de tratamento de desordens musculares
CY1106733T1 (el) Αγωγη νευρολογικης δυσλειτουργιας περιλαμβανουσα σουλφαμικες φρουκτοπυρανοζες και ερυθροποιητινη
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
NO993393D0 (no) Fotokjemoterapeutiske blandinger
DK0841949T3 (da) Anvendelse af saccharid-konjugater
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
EP0824917A3 (en) Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
WO1992012715A3 (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
IL129612A0 (en) Adamantane amines
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2003103675A3 (en) COMBINATION THERAPIES FOR PURINOCEPTOR RELATED DISORDERS
EP1825851A3 (en) Combination therapy for effecting weight loss and treating obesity
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater